DE69133158D1 - Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens - Google Patents

Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens

Info

Publication number
DE69133158D1
DE69133158D1 DE69133158T DE69133158T DE69133158D1 DE 69133158 D1 DE69133158 D1 DE 69133158D1 DE 69133158 T DE69133158 T DE 69133158T DE 69133158 T DE69133158 T DE 69133158T DE 69133158 D1 DE69133158 D1 DE 69133158D1
Authority
DE
Germany
Prior art keywords
delta
weight loss
androstene
beta
promoting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69133158T
Other languages
English (en)
Other versions
DE69133158T2 (de
Inventor
Henry A Lardy
Bruce E Partridge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humanetics Corp
Original Assignee
Humanetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanetics Corp filed Critical Humanetics Corp
Publication of DE69133158D1 publication Critical patent/DE69133158D1/de
Application granted granted Critical
Publication of DE69133158T2 publication Critical patent/DE69133158T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Disintegrating Or Milling (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69133158T 1990-08-29 1991-08-28 Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens Expired - Fee Related DE69133158T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57515690A 1990-08-29 1990-08-29
PCT/US1991/006147 WO1992003925A1 (en) 1990-08-29 1991-08-28 Treatment process for promoting weight loss employing a substituted δ5-androstene
US43981603P 2003-01-13 2003-01-13

Publications (2)

Publication Number Publication Date
DE69133158D1 true DE69133158D1 (de) 2003-01-02
DE69133158T2 DE69133158T2 (de) 2003-07-17

Family

ID=37772553

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69133158T Expired - Fee Related DE69133158T2 (de) 1990-08-29 1991-08-28 Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens

Country Status (10)

Country Link
US (1) US5296481A (de)
EP (1) EP0547151B1 (de)
JP (1) JP2973031B2 (de)
AT (1) ATE227992T1 (de)
AU (1) AU647528B2 (de)
CA (1) CA2090759A1 (de)
DE (1) DE69133158T2 (de)
DK (1) DK0547151T3 (de)
ES (1) ES2184729T3 (de)
WO (2) WO1992003925A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641768A (en) * 1989-11-17 1997-06-24 Loria; Roger M. 5-androstene 3β, 17β diol for treatment
US5807848A (en) * 1990-08-29 1998-09-15 Humanetics Corporation Use of dehydroepeiandrosterone-3-carboxylates to control body weight
DE69133158T2 (de) * 1990-08-29 2003-07-17 Humanetics Corp Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
PT666746E (pt) * 1993-09-02 2001-11-30 Humanetics Corp Delta5-androstenos uteis para promover a manutencao de peso ou perda de peso e processo de tratamento
AU7978794A (en) * 1993-10-13 1995-05-04 Neurocrine Biosciences, Inc. 3,17-dihydroxy-3,7,16 and/or 17-methyl-androst-5-ene compounds, derivatives thereof, and their use
EP0954317B1 (de) 1996-04-09 2007-06-06 The University Of Edinburgh Verwendung von 7-alpha-substituierten steroiden zur behandlung von neuropsychiatrischen erkrankungen
US6686486B1 (en) 1997-05-07 2004-02-03 Padma Marwah Process for effecting allylic oxidation
US5869709A (en) * 1997-05-07 1999-02-09 Humanetics Corporation Process for effecting allylic oxidation
US6252119B1 (en) * 1997-07-28 2001-06-26 Salvador Jorge Antonio Riberiro Copper-catalysed allylic oxidation using alkyl hydroperoxide
WO1999007381A1 (en) * 1997-08-11 1999-02-18 Weider Nutrition International, Inc. Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors
AU738136B2 (en) * 1997-11-19 2001-09-06 Humanetics Corporation Use of delta5-androstene-3beta-ol-7,17-dione in the treatment of lupus erythematosus
AU3088799A (en) 1998-03-18 1999-10-11 Humanetics Corporation Process for effecting allylic oxidation using dicarboxylic acid imides and chromium reagents
US6153606A (en) * 1998-10-16 2000-11-28 Humanetics Corporation Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
FR2793491B1 (fr) * 1999-05-10 2005-01-21 Mayoly Spindler Lab Procede de synthese stereospecifique par oxydation allylique de composes allyliques
CA2670236C (en) 1999-09-30 2012-06-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US7553829B2 (en) * 2000-11-30 2009-06-30 Humanetics Corporation Treatment of chronic fatigue syndrome and fibromyalgia syndrome
FR2818148B1 (fr) * 2000-12-15 2005-06-24 Oreal Composition,notamment cosmetique, renfermant, la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoide
FR2818135B1 (fr) 2000-12-15 2003-02-14 Oreal Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un carotenoide
FR2820745A1 (fr) * 2001-02-14 2002-08-16 Oreal Procedes de preparation de la 7alpha-hydroxy- dehydroepiandrosterone
US6399085B1 (en) 2001-03-05 2002-06-04 Humanetics Corporation Method of moisturizing the skin by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof
US6399084B1 (en) 2001-03-05 2002-06-04 Humanetics Corporation Method for diminishing wrinkles and fine lines of the skin by the topical application of Δ5-androstene-3β-ol-7, 17 dione and metabolizable precursors thereof
US6465446B1 (en) 2001-03-12 2002-10-15 John C. Dykstra Treatment of dermatitis by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof
US6368617B1 (en) 2001-05-15 2002-04-09 Reliv' International, Inc. Dietary supplement
US6746182B2 (en) * 2001-07-27 2004-06-08 Abb Vetco Gray Inc. Keel joint arrangements for floating platforms
FR2830015A1 (fr) * 2001-09-27 2003-03-28 Berkem Sa Compositions a base de derives de steroides
US20060217357A1 (en) * 2003-01-13 2006-09-28 Humanetics Corporation Method of achieving accelerated fat loss by administration of a fat loss accelerating agent to a dieting mammal
US7199116B2 (en) * 2003-01-13 2007-04-03 Humanetics Corporation Method of modulating the basal metabolic rate of a dieting mammal by administration of a metabolic modulating agent to the dieting mammal
WO2004062605A2 (en) * 2003-01-13 2004-07-29 Humanetics Corporation Method of achieving accelerated weight loss by administration of a weight loss accelerating agent to a dieting mammal
US20040242618A1 (en) * 2003-04-01 2004-12-02 Lardy Henry A. Antiandrogens with marginal agonist activity and methods of use
US20050069593A1 (en) * 2003-09-29 2005-03-31 Life Time Fitness, Inc. Nutritional supplement containing 7-Keto-DHEA and conjugated linoleic acid
FR2882556B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
US20080153792A1 (en) * 2006-11-17 2008-06-26 Frincke James M Drug Identification and Treatment Method
US8354396B2 (en) * 2006-11-17 2013-01-15 Harbor Therapeutics, Inc. Drug identification and treatment method
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
DK2273994T3 (en) * 2008-04-03 2016-02-01 Neurmedix Inc PHARMACEUTICAL FORMS OF A MEDICINE
WO2010036822A1 (en) * 2008-09-24 2010-04-01 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
US20100222315A1 (en) * 2008-09-24 2010-09-02 Harbor BioSciencs, Inc. Patient populations and treatment methods
US20100227841A1 (en) * 2008-09-24 2010-09-09 Harbor BioSciencs, Inc. Patient populations and treatment methods
EP2506855A4 (de) * 2009-11-30 2014-07-30 Harbor Biosciences Inc Antikarzinomverbindungen und screeningverfahren

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) * 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
US4511511A (en) * 1982-12-15 1985-04-16 Crozer-Chester Medical Center Prednisolone derivatives
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
EP0133995B1 (de) * 1983-08-02 1992-04-15 Research Corporation Technologies, Inc. Steroide und diese enthaltende therapeutische Zusammensetzungen
DE3418491A1 (de) * 1984-05-18 1985-11-21 Merck Patent Gmbh, 6100 Darmstadt Diaminosaeurederivate
PT84911B (pt) * 1986-05-21 1990-02-08 Research Corp Processo para a preparacao de esteroides uteis como agentes anti-cancerigenos e anti-obesidade
US4897390A (en) * 1987-07-21 1990-01-30 Ruhe Rodney C Novel anti-obesity compounds and method of use
US4898694A (en) * 1987-11-25 1990-02-06 Schwartz Arthur G 17-Hydroxy-steroids
DE69133158T2 (de) * 1990-08-29 2003-07-17 Humanetics Corp Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens

Also Published As

Publication number Publication date
ES2184729T3 (es) 2003-04-16
AU647528B2 (en) 1994-03-24
WO2004062606A2 (en) 2004-07-29
US5296481A (en) 1994-03-22
AU8541891A (en) 1992-03-30
WO1992003925A1 (en) 1992-03-19
EP0547151B1 (de) 2002-11-20
EP0547151A4 (en) 1993-10-13
DE69133158T2 (de) 2003-07-17
ATE227992T1 (de) 2002-12-15
DK0547151T3 (da) 2003-03-17
JP2973031B2 (ja) 1999-11-08
EP0547151A1 (de) 1993-06-23
WO2004062606A3 (en) 2004-11-25
JPH06508345A (ja) 1994-09-22
CA2090759A1 (en) 1992-03-01

Similar Documents

Publication Publication Date Title
DE69133158T2 (de) Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens
NO985575L (no) FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese
FI942965A0 (fi) Taimien kasvatusmenetelmä ja -laite
ATE195530T1 (de) 17-ether und thioether von 4-aza-steroiden
ES2098356T3 (es) Derivados de acido 3-aril-2-hidroxipropionico y analogos como agentes hipoglucemicos.
ES2017808A6 (es) Un metodo para prepara una composicion para inhibir el crecimiento indeseado o patologico de celulas o tejidos.
AU562646B2 (en) 1-alkyl-androsta-1, 4-diene-3, 17-diones
DE68918944D1 (de) Künstliche rezeptor-analoge.
DE69634472D1 (de) Adrenal-Cortikosteroide enthaltende therapeutische Zusammensetzung zur äusserlichen Anwendung für Dermatitis-Behandlung
GR3036666T3 (en) -g(D)5-ANDROSTENES USEFUL FOR PROMOTING WEIGHT MAINTENANCE OR WEIGHT LOSS AND TREATMENT PROCESS.
PL237211A1 (en) Agent for fighting against or preventing contagion with microorganisms and/or for controlling plant growth as well as method of obtaining new substituted derivatives of 1-azolilo-2-hydroxypropane
DE69010025D1 (de) Verfahren zur Herstellung von 14-Alpha-hydroxy-4-androsten-3,6,17, trion.
DE69115745D1 (de) Verwendung von Steroidderivaten zur Behandlung der Endometriose
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
NZ515393A (en) Compositions and process for nematode control
MY102572A (en) Selective method-of-use of oxabicycloalkanes
PT80008B (en) A process for the preparations of a 2alpha-cyano-4alpha,alpha5--epoxyandrostan-3,17-dione
MX9700227A (es) Metodo para preparar ganado vacuno para ser sacrificado.
JPS6470061A (en) Deodorant for livestock and its preparation
DE69532959D1 (de) D-ring modifizierte gibberellinverbindungen und ihre herstellung und verwendung
UA19671A (uk) Спосіб боротьби з фітопатогеhhими мікрооргаhізмами
FR2421911A2 (fr) Nouveaux derives du pregn 4-ene, leur procede de preparation et leur application comme medicament

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee